| Name | 2-(4-Fluorophenyl)-6-methyl-4-[3-(trifluoromethyl)phenyl]-1,6-dihydrodipyrazolo[3,4-b:3',4'-d]pyridin-3(2H)-one |
|---|---|
| Synonyms |
Dipyrazolo[3,4-b:3',4'-d]pyridin-3(2H)-one, 2-(4-fluorophenyl)-1,6-dihydro-6-methyl-4-[3-(trifluoromethyl)phenyl]-
2-(4-Fluorophenyl)-6-methyl-4-[3-(trifluoromethyl)phenyl]-1,6-dihydrodipyrazolo[3,4-b:3',4'-d]pyridin-3(2H)-one CTLA-4 - INHIBITOR |
| Description | B7/CD28 interaction inhibitor 1 is a potent B7.1-CD28 interaction inhibitor with an IC50 of 50 nM[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 50 nM (B7.1-CD28 interaction)[1] |
| In Vitro | Bivalent CTLA4 homodimers bridge bivalent B7.1 homodimers to form an unusually stable signaling complex. Blocking B7/CD28 interactions with monoclonal antibodies or soluble receptors results in immunosuppression and enhanced allograft survival, while B7/CTLA-4 blockade results in enhanced antitumor immune responses. The interaction of co-stimulatory molecules on T cells with B7 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases[1]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 599.5±60.0 °C at 760 mmHg |
| Molecular Formula | C21H13F4N5O |
| Molecular Weight | 427.354 |
| Flash Point | 316.4±32.9 °C |
| Exact Mass | 427.105621 |
| LogP | 3.80 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.677 |
| Storage condition | -20℃ |